Elevance Health stock holds at $400 as analysts stay positive
Published on 08/17/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (US2855211023) stock is trading close to $400 in mid-August 2026, supported by an earnings beat in July and a broadly positive analyst consensus that still sees upside from current levels as of August 17, 2026.
Price levels and recent performance
Market data show Elevance Health shares at $400.32, with the last regular-session close recorded on August 14, 2026 at 4:00 p.m. ET. A recent quote snapshot indicates the stock gained 0.52% in that session, adding $2.08 on the day.
The same data set puts Elevance Health's market capitalization at $86.81 billion as of that close, underlining that the company remains one of the larger managed-care and health-benefits players in the United States. The quote overview also shows a twelve month trading range with a low of $274.84 and a high of $436.24 reported in recent coverage, meaning the current price is trading below the top of that band but well above the lower end.
For context, a separate comparison tool lists Elevance Health at $400.32 alongside other large-cap names as of August 17, 2026, confirming that the stock price has been holding in the low $400s in recent days rather than breaking to new extremes. The comparison snapshot shows Elevance Health priced above some industrial peers yet still below certain healthcare names, reinforcing the impression of a steady rather than euphoric market valuation.
Earnings beat and guidance backdrop
The latest reported quarter provides the fundamental backdrop for this price level. A recent earnings summary notes that Elevance Health released its quarterly results on July 15, 2026, reporting earnings per share of $7.45.
That $7.45 EPS figure topped consensus estimates of $6.21, delivering a positive surprise of $1.24 per share in the quarter ended in mid-2026. According to the same summary, revenue reached $49.83 billion in that period, ahead of the $48.88 billion analysts had been expecting. The reported revenue increase of 0.8% over the same quarter a year earlier shows only modest top-line growth, but the EPS beat suggests solid cost control and underwriting discipline.
Profitability metrics in the report underline that Elevance Health continues to generate returns above its cost of capital. The earnings overview cites a return on equity of 14.64% in the latest quarter and a net margin of 2.47%, both current figures for this reporting period. Sell-side forecasts compiled there point to full-year earnings per share of 27.07 for the current year, indicating that if quarterly performance tracks expectations, Elevance Health could deliver double-digit annual EPS with room for further capital returns.
Analyst view and institutional flows
Analysts have broadly reacted favorably to the company following the July results. Multiple coverage summaries state that Elevance Health holds an average recommendation described as a moderate buy, with a consensus price target around $440.90. One consensus overview highlights the same target and rating language, reflecting a view that the stock could rise roughly 10% from the current $400 region if the company delivers on expectations.
Several recent filings point to continued interest from institutional investors. A filing summary notes a new $12.12 million position from Firetrail Investments PTY Ltd in Elevance Health, while other overviews mention fresh stakes in the low- to mid-single-digit million-dollar range from different wealth management firms. The Firetrail transaction recap places these investments in the context of a stock seen as reasonably valued after the earnings beat.
Dividend policy adds another element to the return profile. The earnings recap notes a recently announced quarterly dividend of $1.72 per share, with the payout scheduled for September 25, 2026 and a record date of September 10, 2026. On an annualized basis that $1.72 quarterly dividend corresponds to $6.88 per share, translating into a dividend yield of 1.7% at the $400.63 opening level cited in the same report. The combination of a modest yield and double-digit expected EPS growth positions Elevance Health as a total-return story rather than a pure income name.
Product focus: health benefits platform
Elevance Health's core offering is an integrated health-benefits platform that combines medical insurance, pharmacy benefits, and associated services for employer groups, individuals, and government programs. The company structures these services to manage medical cost trends while aiming to improve care quality, using claims data, provider-network strategies, and care-management tools to influence outcomes. For investors, the stability of this core product line, along with incremental innovation around data and digital tools, helps explain why earnings can outpace modest revenue growth in a mature market.
Stock context for US investors
Elevance Health trades on the New York Stock Exchange under the ticker ELV, with the latest widely cited closing price of $400.63 as of August 14, 2026 at 3:59 p.m. ET. That level stands below the consensus target but well above the twelve month low, suggesting that a significant portion of the expected upside identified by analysts has already been realized, while some potential remains if the company continues to beat earnings expectations and sustain its dividend policy.
Read more
Further details on Elevance Health stock, including live quotes and additional analyst commentary, can be found in the linked quote overview and earnings recap in this article.
Fact box
Company: Elevance Health Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: NYSE
Price (as of August 14, 2026, 3:59 p.m. ET): $400.63 USD
Market cap: $86.81 billion (as of August 14, 2026)
Sector / Industry: Health care - managed care and benefits
Index membership: S&P 500
Next earnings date:
